1.
Angiol Sosud Khir
; 24(4): 33-42, 2018.
Artigo
em Inglês, Russo
| MEDLINE
| ID: mdl-30531767
RESUMO
For 15 years, from 2001, we began to apply Heberprot-P®, an injectable Epidermal Growth Factor (0.75 µg) created in the Center of Biotechnology, in Havana, Cuba. More than 159,000 patients were treated around the world, from 25 countries, with, with only 9-11% high-level amputations. In this paper, we discuss our experience in the treatment of the most complex diabetic foot ulcers cases for the last 15 years.